Navigation Links
New Lupus Drug Results From Scripps Research Technology
Date:3/9/2011

LA JOLLA, Calif., March 9, 2011 /PRNewswire/ -- Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

"I am deeply gratified that our scientific findings have proven so valuable to drug discovery," said Richard A. Lerner, MD, president of Scripps Research. "This development underlines the importance of basic academic science in laying important groundwork for life-saving medical advances."

Benlysta®, developed by GlaxoSmithKline and Human Genome Sciences, is the first new drug treatment for lupus in 50 years.

Short-Circuiting the Cycle of Lupus

Benlysta® was approved for systemic lupus erythematosus, a chronic, life-threatening inflammatory disease affecting the joints, skin, kidneys, blood, heart, and lungs. It is often simply referred to as "lupus" (although there are other types of lupus, including one that affects solely the skin). Estimates of the number of Americans affected by sytemic lupus erythematosus range from 161,000 to 1.5 million, according to the U.S. Centers for Disease Control. Lupus can occur at any age, but first appears largely in 15- to 40-year-olds, the majority of whom are women.

Lupus is an autoimmune disease, which occurs when a person's body produces an immune response against its own tissues instead of solely attacking foreign invaders such as viruses, bacteria, and other toxins.

Symptoms can include debilitating fatigue, painful and swollen joints, fever, skin rash, and kidney problems. The disease can also lead to arthritis, kidney failure, heart and lung inflammation, central nervous system abnormalities, inflammation of the blood vessels, and blood disorders.


'/>"/>
SOURCE The Scripps Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
2. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
3. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
6. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NORWALK, Conn. , Oct. 22, 2014  Recently ... (GERD) have bolstered the already substantial database of evidence. ... and adoption of Stretta therapy for sufferers ... of clinical evidence supporting Stretta therapy as ... coverage policies that make Stretta therapy available to nearly ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Valeritas, Inc., a leader in simple, disposable ... 2 diabetes, announced today that it has received a ... was presented October 16 th at Cardinal,s annual ... . The Cardinal Health Supply Chain ... metrics specifically targeted at the importance of developing collaborative ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... , MAPLE GROVE, Minn., Dec. 3 Upsher-Smith ... plan for central nervous system (CNS) diseases with USL255 (extended ... epilepsy. USL255 is being developed with Upsher-Smith,s proprietary formulation technology ... 2010 for the adjunctive treatment of epilepsy patients with partial ...
... , HARRISBURG, Pa., Dec. 3 ... processing company build a new cold storage facility and ... at least 20 jobs, Governor Edward G. Rendell announced ... more than $2.9 million for three projects. The investments, ...
Cached Medicine Technology:Upsher-Smith Announces Milestone in Development of CNS Strategy 2Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia 2
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... (TSX: RBM, OTCBB: RPBIF) reported that it recorded ... $13,901,041 or ($0.12) per share,for the year ended ... of December 31, 2007 it had approximately $8.2 ... the Company,s financial results for,the year ended December ...
... China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ) ... the research, development, manufacture,and marketing of pharmaceutical, nutritional ... China ("PRC"), today announced it will,conduct a conference ... 2, 2008, to,discuss the Company,s financial results for ...
... NMHC,s Stockholders Accept ... SXC,s ... -,SXC Health Solutions Corp. ("SXC") (Nasdaq: SXCI ; TSX: SXC) ... jointly announced,today that, pursuant to their previously announced merger agreement, SXC ...
... finds uncertainty about risks and benefits of mastectomies or ... half the women diagnosed with early-stage breast cancer clearly ... a breast-conserving lumpectomy plus radiation, even after they have ... , If the woman is black or Hispanic, the ...
... CNS Response,Inc. (OTC Bulletin Board: CNSO) ... roll out referenced-EEG(R) (rEEG(R)) availability with an,undisclosed, ... enables psychiatrists under the management of the ... to treat their most,therapy-challenged patients suffering any ...
... 31 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider ... announced the opening of its 76th LasikPlus(R) vision,center ... fourth,LasikPlus(R) vision center opened this year, and the ... opened a LasikPlus(R) vision,center in Paramus in April ...
Cached Medicine News:Health News:Response Biomedical Corporation Reports 2007 Financial Results 2Health News:Response Biomedical Corporation Reports 2007 Financial Results 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 4Health News:Response Biomedical Corporation Reports 2007 Financial Results 5Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 5Health News:Many Women Unclear About Breast Cancer Treatments 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 3Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 4Health News:LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey 2
... E-Gel® 96 and E-Gel® 48 ... E-Base™ electrophoresis bases, which combine the ... device. , The mother E-Base™ power ... can be connected directly to an ...
... Turn routine agarose gel electrophoresis into ... 96 system. This bufferless, pre-cast system is ... preparations, restriction digests, and more. Fully automated, ... the E-Gel 96 system makes your high-throughput ...
... System provides a compact format to rapidly ... PCR products and synthetic oligonucleotides, while using ... Horizontal Unit has gel bed dimensions of ... bed is UV transparent. Adjustable height Combs ...
... for very fast and clear separation of DNA restriction ... to cast, run, and perform Southern or Northern blotting ... electrophoresis tank and cover, 1 x Gel Maker Stand ... x MT-T02 (50 x 60 mm tray), 1 x ...
Medicine Products: